Durch interne Emitter verursachte strahleninduzierte Nephropathie: Dosis-Effektbeziehungen, Prophylaxe und Therapie im präklinischen Modell der Radiopeptidtherapie neuroendokriner Tumoren

Radiopeptide therapies are used in the treatment of malignant tumors, such as the medullary thyroid carcinoma or the SCLC. Radiolabeled Minigastrin is able to locate metastasis in an earlier state then it is possible with other diagnostic methods. The dose-limiting organ is the kidney. In such therapies a radiation nephropathy may result using higher activities. Prophylaxis is more important then treatment. The extent of a radiation-induced nephropathy varies depending on the used emitter. Auger/conversion-electron (e.g. 111In)emitters are high-LET emitters with a very short path length and do less harm to the radiosensitive structures of the kidney then ß- or a-emitters. Antioxidant substances may play an important role as well. Amifosin and selenide have a protective effect, other vitamins (A,C,E) do not significantly effect the developing of a radiation nephropathy. Drugs affecting the renin-angiotensin-system will lead to a more severe form of radiation nephropathy, when they are given after the radiation.